Cancer

Peer-Reviewed Publication China Anti-Cancer Association image: Potential pro- and anti-tumor functions of tumor-associated neutrophils (TANs). TANs may either promote or inhibit tumorigenesis and tumor progression through various immune mechanisms. (Figure left) Anti-tumor roles of TANs, which involve direct tumor cytotoxicity through secretion of protease granules, like reactive oxygen species (ROS) and myeloperoxidase (MPO). Additionally, TANs […]

by Mass General Brigham edited by Sadie Harley, reviewed by Andrew Zinin Credit: Ivan Samkov from Pexels For patients with a cancer diagnosis, early specialty palliative care is considered the standard of care. However, many patients with advanced cancer do not consistently receive specialty palliative care, especially during the early stages of their illness. Isaac Chua, MD, MPH,

MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (bsAbs). These novel approaches have delivered unprecedented outcomes in heavily pretreated patients. Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025